Company news

GSK plc news in 2025

GSK plc's news releases, calls and decks from 2025, newest first.

View company

Arexvy filed in Japan for 18-49 at increased risk

June 20, 2025

GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US

June 16, 2025

GSK submits Arexvy for adults 18+ with EMA

June 13, 2025

GSK - second tranche of share buyback programme

June 4, 2025

Linerixibat file accepted for review by US FDA

June 2, 2025

GSK stops Phase 3 trial on cUTIs for efficacy

May 28, 2025

positive CHMP opinion on Blenrep in EU

May 23, 2025

FDA approves Nucala COPD indication

May 23, 2025

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

May 22, 2025

Blenrep for 2L+ multiple myeloma approved in Japan

May 19, 2025

GSK to acquire efimosfermin

May 14, 2025

Update on belrestotug development programme

May 13, 2025

GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

May 9, 2025

Linerixibat GLISTEN pIII trial data at EASL

May 8, 2025

Result of AGM

May 7, 2025

Nucala MATINEE data in COPD published in NEJM

May 1, 2025

1st Quarter Results

April 30, 2025

Blenrep licensed by UK MHRA

April 17, 2025

Arexvy now ACIP recommended for 50-59 at risk

April 17, 2025

GSK 5-in-1 meningitis vaccine recommended in US

April 17, 2025

GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices

April 16, 2025

GSK Awards $2M in Grant Funding for Programs Supporting Adult Vaccination, Commits Additional $2M for 2025

April 9, 2025

Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older

March 25, 2025

GSK uUTI treatment approved by US FDA

March 25, 2025

Notice of AGM

March 24, 2025

EMA Filing acceptance for Nucala COPD

March 24, 2025

GSK plc 2024 Annual Report on Form 20-F

March 3, 2025

US FDA accept 2 depemokimab indication submissions

March 3, 2025

ANCHOR results presented at 2025 AAAAI

March 3, 2025

GSK publishes Annual Report 2024

February 27, 2025

GSK completes acquisition of IDRx, Inc.

February 24, 2025

GSK plc commences share buyback programme

February 24, 2025

Directorate Change

February 21, 2025

Nucala COPD submission accepted in China

February 20, 2025

GSK 5-in-1 meningitis vaccine approved by US FDA

February 17, 2025

Depemokimab dual filing in China and Japan

January 28, 2025

EMA accepts two submissions for depemokimab

January 28, 2025

EMA accept review Shingrix syringe presentation

January 27, 2025

Jemperli expanded approval in the EU

January 20, 2025

GSK enters agreement to acquire IDRx, Inc.

January 13, 2025

Shingrix fully liquid accepted for US FDA review

January 10, 2025

GSK ADC gets FDA breakthrough therapy designation

January 7, 2025

GSK’s Nucala approved in China for use in CRSwNP

January 3, 2025

← Newer news releases

Calls in 2025

Decks in 2025